Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations / Advanced Breast Cancer Therapies · Journal article
Future Oncology · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a descriptive, retrospective analysis of pharmacy dispensing records for tepotinib in 436 metastatic NSCLC patients, measuring treatment persistence and adherence rather than clinical efficacy or safety. The study reports high adjusted adherence (mean PDC 94.9%) and shows that dose reduction (14.7% of patients) did not prevent continued therapy, but lacks clinical outcomes, efficacy comparison, or formal safety assessment to support practice change.
Exploratory, retrospective cohort study. Adults aged ≥50 years with metastatic non-small cell lung cancer receiving tepotinib via specialty pharmacy dispensing.. Intervention: Tepotinib (MET inhibitor) for metastatic NSCLC; dose reductions permitted.. n = 436. United States (McKesson pharmacy network); specific centres not named..
Full cohort (n=436, median age 71 years) had median days supplied 120 (range 15–1,950) and median days covered 119 (15–1,388) Mean unadjusted proportion of days covered (PDC) was 72.9%; adjusted PDC (accounting for gaps >42 days) was 94.9% Dose reduction occurred in 64 patients (14.7%); among these, median days supplied and covered since reduction were 120 (30–870) and 120 (30–857) days
No clinical outcomes (response, survival, progression-free survival) reported; pharmacy data alone cannot assess efficacy or safety Reasons for discontinuation and dose reduction not specified; cannot distinguish tolerability from disease progression or patient choice
This work describes real-world treatment patterns and adherence to tepotinib but does not establish clinical efficacy, safety, or whether observed adherence translates to improved outcomes. Clinicians should interpret these findings as supporting operational feasibility of tepotinib dosing and dose reduction strategies, pending outcome data.
Real-world retrospective pharmacy data on persistence and adherence without clinical outcomes, efficacy comparison, or prospective validation; describes treatment patterns rather than clinical benefit or harm.
As stated by the source record.
Quoted from the source exactly as published.
This work describes real-world treatment patterns and adherence to tepotinib but does not establish clinical efficacy, safety, or whether observed adherence translates to improved outcomes. Clinicians should interpret these findings as supporting operational feasibility of tepotinib dosing and dose reduction strategies, pending outcome data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
AIM: This study evaluated the real-world persistence, adherence, treatment discontinuation, and dose reduction of tepotinib in patients with metastatic non-small cell lung cancer (NSCLC). METHODS: This exploratory, retrospective study used McKesson's Biologics Specialty Pharmacy shipment data (10 February 2021-07 April 2025). Adults ≥50 years with NSCLC receiving tepotinib were included. Persistence was assessed as days supplied and covered; adherence as proportion of days covered (PDC), unadjusted and adjusted for gaps >42 days. Dose modifications, discontinuations, and time to last discontinuation were evaluated. Outcomes were assessed in the full cohort and a dose reduction subgroup. RESULTS: Full cohort included 436 patients (median age: 71 years; follow-up: 6.4 months). Median (range) days supplied and covered were 120 (15-1,950) days and 119 (15-1,388) days, respectively. Mean unadjusted PDC was 72.9% and adjusted PDC was 94.9%. Dose reduction was observed in 64 (14.7%) patients. Among these, median days supplied and covered since dose reduction were 120 (30-870) days and 120 (30-857) days, respectively. Mean unadjusted PDC was 78.1% and adjusted PDC was 92.7%. CONCLUSION: Tepotinib therapy showed consistent real-world persistence and adherence among patients with metastatic NSCLC. Dose reductions supported continuity of tepotinib therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.